COVID-19 Coding and Reporting Information
New CPT®, HCPCS, and ICD-10 CM Codes

Last updated 4/15/20

This resource provides an overview of CPT, HCPCS, and ICD-CM codes related to COVID-19 treatment and testing. This is being provided as an informational resource for ASCO members and should not be considered as official payment guidance. ASCO members are encouraged to confer directly with payers (both Medicare and private) for appropriate reporting guidelines, as they may vary by payer.


New CPT ® codes have been developed to describe coronavirus testing provided by hospitals, health systems, and laboratories in the United States.

In addition to CPT® code 87635, two new codes were created to report serologic laboratory testing. CPT® codes 86328 and 86769 are effective immediately to report the appropriate laboratory tests. Contact your third-party payers to confirm reimbursement, policies, and reporting guidelines.

86328- Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

86769 -Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

CPT ® code 86318 has also been revised to reflect updates in testing:

86318- Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip)

87635-Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique

CPT ® code 87635 differs from current CPT codes that mention coronavirus in the descriptor (87631, 87632, and 87633) in that it is specifically for the detection of SARS-CoV-2 (COVID-19) and any pan-coronavirus types or subtypes, and it can be reported with tests from multiple manufacturers using the stated technique.

Though CPT ® code 87635 is effective as of March 13th, 2020, it will not be published until 2021. Therefore, the code will need to be manually uploaded it into your EHR system.

"CPT Copyright 2020 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association."
Healthcare Common Procedure Coding System (HCPCS) Codes

The Centers for Medicare & Medicaid Services (CMS) also developed two new Healthcare Common Procedure Coding System (HCPCS) codes for coronavirus testing to be used for Medicare claims. They should not be used for private payer claims unless otherwise directed.

HCPCS Code Descriptions

U0001- Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel

U0002- 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc

HCPCS code U0001 should be used specifically for Centers for Disease Control and Protection (CDC) testing laboratories to test patients for SARS-CoV-2 (CDC 2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel), while U0002 allows laboratories to bill for non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19).

HCPCS Code Payment Rates

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>National Payment Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>U0001- 2019-ncov diagnostic p</td>
<td>$35.91</td>
</tr>
<tr>
<td>U0002- Covid-19 lab test non-cdc</td>
<td>$51.31</td>
</tr>
</tbody>
</table>

Claims processing systems will begin accepting these codes on April 1, 2020 for dates of service on or after February 4, 2020.

For original Medicare, beneficiaries will have zero cost sharing (as with other lab tests).

Cost Sharing

Effective March 18th, 2020 until the end of the Public Health Emergency, CMS is waiving coinsurance and deductible amounts under Medicare Part B for Medicare patients for certain COVID-19 testing-related services. The cost sharing waiver applies to medical visits when an outpatient provider, physician, or other providers and suppliers that bill Medicare for Part B services orders or administers COVID-19 lab tests U0001, U0002, or 87635.

Services/Visits for Which Cost Sharing is Waived

- Services resulting in an order for or administration of a COVID-19 test
- Services related to furnishing or administering such a test or to the evaluation of an individual for purposes of determining the need for such a test;
- Any of the following categories of HCPCS evaluation and management codes:

"CPT Copyright 2020 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association."
Office and other outpatient services
Hospital observation services
Emergency department services
Nursing facility services
Domiciliary, rest home, or custodial care services
Home services
Online digital evaluation and management services

CMS has also implemented a no cost-sharing requirement for group health plans and group and individual health insurance to cover both diagnostic testing and certain related items and services provided during a medical visit. This includes urgent care visits, emergency room visits, and in person telehealth visits that result in an order for or administration of a COVID-19 test.

**Reporting Information**

For Medicare claims, to indicate that a service is subject to the cost-sharing waiver the CS modifier must be added to the appropriate claim lines. If claims were submitted to Medicare without the CS modifier, notify the Medicare Administrative Contractor (MAC) and request to submit the applicable claims.

These reporting instructions apply to Medicare beneficiary claims - check with private payers for their specific reporting guidelines.

**ICD-10 CM Codes**

The Centers for Disease Control and Prevention (CDC) has developed coding guidance for health care encounters and deaths related to the 2019 novel coronavirus (COVID-19).

In certain circumstances, other codes for conditions not related to coronavirus may be required in accordance with the ICD-10-CM Official Guidelines for Coding and Reporting. A hyphen at the end of a code indicates an additional character is required.

**Coronavirus Infection**

**Code Description**

U07.1-COVID-19, virus identified

**Coding Instructions**

In response to the national emergency that was declared concerning the COVID-19 outbreak, a new diagnosis code, U07.1, COVID-19, has been implemented, effective April 1, 2020.

ICD-10 code U07.1 may be reported if:

- If the patient has a confirmed diagnosis of the 2019 novel coronavirus disease (COVID-19) as documented by the provider;

"CPT Copyright 2020 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association."
• Documentation of a positive COVID-19 test result; or
• A presumptive positive COVID-19 test result. A presumptive positive test result is defined as an “individual has tested positive for the virus at a local or state level, but it has not yet been confirmed by the Centers for Disease Control and Prevention (CDC).

If COVID is the principal diagnosis, it should be listed first and then followed by the appropriate codes for associated manifestations.

Do not report U071.1 if the providers documentation indicates the patient’s condition is "suspected," "possible," "probable," or “inconclusive” COVID19. In that case, report a code(s) indicating the reason for encounter (ex. a fever) or Z20.828 (Contact with and (suspected) exposure to other viral communicable diseases).

Pneumonia
For a pneumonia case confirmed due to the 2019 novel coronavirus (COVID-19) assign codes:

J12.89 - Other viral pneumonia and

B97.29 - Other coronavirus as the cause of diseases classified elsewhere

Acute Bronchitis
For a patient with acute bronchitis confirmed as due to COVID-19, assign codes:

J20.8 - Acute bronchitis due to other specified organisms and

B97.29 - Other coronavirus as the cause of diseases classified elsewhere

Bronchitis not otherwise specified (NOS) due to the COVID-19 should be coded using code:

J40 - Bronchitis, not specified as acute or chronic along with

B97.29 - Other coronavirus as the cause of diseases classified elsewhere

Lower Respiratory Infection
If the COVID-19 is documented as being associated with a lower respiratory infection, not otherwise specified (NOS), or an acute respiratory infection, NOS, assign codes:

J22 - Unspecified acute lower respiratory infection with

B97.29 - Other coronavirus as the cause of diseases classified elsewhere

If the COVID-19 is documented as being associated with a respiratory infection, NOS, assign code:

J98.8 - Other specified respiratory disorders with

"CPT Copyright 2020 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association."
B97.29 - Other coronavirus as the cause of diseases classified elsewhere

**Acute respiratory distress syndrome (ARDS)**
Cases with ARDS due to COVID-19 should be assigned the codes:
J80 - Acute respiratory distress syndrome
B97.29, Other coronavirus as the cause of diseases classified elsewhere

**Exposure to COVID-19**
For cases where there is a concern about a possible exposure to COVID-19, but is ruled out after an evaluation, it would be appropriate to assign the code:
Z03.818 - Encounter for observation for suspected exposure to other biological agents ruled out
For cases where there is an actual exposure to someone confirmed to have COVID-19, assign the code:
Z20.828 - Contact with and (suspected) exposure to other viral communicable diseases

**Signs and symptoms**
For patients with any signs/symptoms (such as fever, etc.) and where a definitive diagnosis has not been determined, assign the appropriate code(s) for each of the presenting signs and symptoms such as:
R05 - Cough
R06.02 - Shortness of breath
R50.9 - Fever, unspecified

The diagnosis code B34.2 (Coronavirus infection, unspecified) would in general not be appropriate for the COVID-19, as the cases have universally been respiratory in nature. Therefore, the site would not be “unspecified.”

If the provider documents “suspected”, “possible” or “probable” COVID-19, *do not* assign code B97.29 (Other coronavirus as the cause of diseases classified elsewhere). Assign a code or codes explaining the reason for encounter, such as fever, or Z20.828 (Contact with and (suspected) exposure to other viral communicable diseases).
Resources

Centers for Medicare and Medicaid Services
- Update to the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) for Vaping Related Disorder and 2019 Novel Coronavirus (COVID-19) (April 1, 2020)
- Update to the Home Health Grouper for New Diagnosis Code for Vaping Related Disorder and COVID-19
- MLN Connects: Friday, April 10th 2020
- FAQS ABOUT FAMILIES FIRST CORONAVIRUS RESPONSE ACT AND CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY ACT IMPLEMENTATION PART 42
- Public Health News Alert: CMS Develops New Code for Coronavirus Lab Test
- Coverage and Payment Related to COVID-19

Centers for Disease Control and Prevention
- ICD-10-CM Official Coding Guidelines - Supplement Coding encounters related to COVID-19 Coronavirus Outbreak
- ICD-10-CM Official Coding and Reporting Guidelines April 1, 2020 through September 30, 2020

World Health Organization
- COVID-19 coding in ICD-10

American Hospital Association
- AHA: Frequently Asked Questions Regarding ICD-10-CM Coding for COVID-19

American Medical Association
- April Update: SARS-CoV-2 Serologic Laboratory Testing
- AMA Fact Sheet: Reporting Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Laboratory Testing
- CPT reporting for COVID-19 Testing
- Special coding advice during COVID-19 public health emergency

Coding and Billing Questions
- Questions regarding billing and coding can be sent to ASCO at billingandcoding@asco.org.